BCBA/AZN (BCBA/AZN)

Buenos Aires Stock Exchange: BCBA/AZN · ARS

ARS 70,225

-1726.84 (-2.4%)· Recorded snapshot

Market cap	407.1T
Revenue (ttm)	90.9T
Net income (ttm)	15.5T
EPS (ttm)	ARS 2,769
P/E (trailing)	25.4x
P/E (forward)	15.8x
Dividend	ARS 1,041 (1.48%)
Volume	1,295

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 90.9T
Net income (ttm): 15.5T
EPS (ttm): ARS 2,769
P/E (trailing): 25.4x
P/E (forward): 15.8x
Market cap: 407.1T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E15.8

P25 n/aP50 n/aP75 n/a

Trailing P/E25.4

P25 n/aP50 n/aP75 n/a

ROE22

P25 n/aP50 n/aP75 n/a

ROIC16.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BCBA/AZN indicators

Market & fundamental data

Available fields

245

Groups with data

Currency

USD

Showing 245 of 245 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	ARS
Country	United Kingdom
Country code	AR
Earnings date	2026-10-30
Employees	96,100
Employees change	1,800
Employees growth	1.91%
Enterprise value	ARS 449.4T
Exchange	Buenos Aires Stock Exchange
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-10
Fiscal year end	December
Founded	1992
Industry	Drug Manufacturers - General
Is primary listing	No
ISIN number	ARDEUT112489
Last earnings date	2026-07-27
Last refreshed	2026-10-28
Market cap	ARS 407.1T
Next earnings date	2026-10-30
Price	ARS 70,225.00
Price currency	ARS
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-27
Symbol	bcba/AZN
Website	https://www.astrazeneca.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	84.65x
Average P/E ratio (3Y)	30.99x
Average P/E ratio (5Y)	130.79x
Earnings yield	3.94%
EV/Earnings	29.04x
EV/EBIT	19.46x
EV/EBITDA	14.11x
EV/FCF	28.44x
EV/Sales	4.75x
FCF / EV yield	3.52%
FCF yield	3.88%
Forward P/E	15.78x
Graham number	27808.76091
Graham upside	-60.4%
Lynch fair value	ARS 60,343.77
Lynch upside	-14.07%
P/(FCF - SBC) ratio	26.67x
P/(OCF - SBC) ratio	20.61x
P/B ratio	5.45x
P/E ratio	25.36x
P/FCF ratio	25.76x
P/OCF ratio	20.06x
P/S ratio	4.48x
Price/EBITDA ratio	13.57x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	24.42%
EBITDA margin	33%
Effective tax rate	16.95%
FCF margin	16.74%
Gross margin	81.69%
Operating margin	24.42%
Pretax margin	20.51%
Profit margin	17.02%
Profit per employee	ARS 161M
Profitable quarters	18
Profitable years	36
Revenue per employee	ARS 946M
ROA	8.21%
ROA (5Y)	5.95%
ROCE	17.78%
ROE	21.96%
ROE (5Y)	13.03%
ROIC	16.43%
ROIC (5Y)	13.29%
SBC / revenue	0.6%
Tax / revenue	3.48%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	25.84%
EPS growth (Q)	2.55%
EPS growth (QoQ)	-18.27%
EPS growth 10Y	14.33%
EPS growth 3Y	19.13%
EPS growth 5Y	18.4%
EPS growth years	4
FCF growth	-4.55%
FCF growth (Q)	-22.92%
FCF growth (QoQ)	-25.25%
FCF growth 3Y	5.66%
FCF growth 5Y	14.81%
Gross profit growth	7.69%
Gross profit growth (Q)	7.25%
Gross profit growth 3Y	9.19%
Gross profit growth 5Y	17.24%
Net income growth	25.93%
Net income growth (Q)	2.33%
Net income growth (QoQ)	-18.6%
Net income growth 3Y	19.23%
Net income growth 5Y	22.6%
Net income growth years	4
OCF growth	2.32%
OCF growth (Q)	-15.39%
OCF growth (QoQ)	-14.71%
OCF growth 10Y	14.02%
OCF growth 3Y	10.41%
OCF growth 5Y	16.27%
Operating income growth	5.8%
Operating income growth (Q)	2.88%
Operating income growth 3Y	9.95%
Operating income growth 5Y	31.31%
Revenue growth	8.61%
Revenue growth (Q)	6.41%
Revenue growth (QoQ)	0.63%
Revenue growth 10Y	9.81%
Revenue growth 3Y	11.32%
Revenue growth 5Y	15.75%
Revenue growth quarters	13
Revenue growth years	7

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	ARS -4.5T
Depreciation and amortization	ARS 8.1T
EBIT	ARS 22.2T
EBITDA	ARS 30T
EPS	ARS 2,768.69
Financing cash flow	ARS -11.4T
Free cash flow	ARS 15.8T
Free cash flow minus SBC	ARS 15.3T
Gross profit	ARS 74.3T
Income taxes	ARS 3.2T
Investing cash flow	ARS -12.1T
Net borrowing	ARS -2.9T
Net cash flow	ARS -3.2T
Net income	ARS 15.5T
Operating cash flow minus SBC	ARS 19.8T
Operating income	ARS 22.2T
Revenue	ARS 90.9T
Stock-based compensation	ARS 542.2B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	3.58
Book value per share	ARS 48,041.29
Debt / EBITDA	1.57
Debt / equity	0.64
Debt / FCF	3.03
Goodwill	ARS 32.6T
Interest coverage	10.64
Long-term assets	ARS 128.6T
Long-term liabilities	ARS 48.4T
Net cash (debt)	ARS -40.6T
Net cash / market cap	-9.97%
Net debt / EBITDA	1.35
Net debt / equity	0.54
Net debt / FCF	2.57
Piotroski F-Score	7
Property, plant and equipment	ARS 25.1T
Shareholders' equity	ARS 74.6T
Tangible book value	ARS -12.8T
Tangible book value per share	ARS -8,223.23
Total assets	ARS 171.6T
Total cash	ARS 7.4T
Total debt	ARS 47.9T
Total liabilities	ARS 97T

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.54
Current assets	ARS 43T
Current liabilities	ARS 48.5T
Current ratio	0.89
Inventory turnover	1.68
Net working capital	ARS -3.3T
Quick ratio	0.66
Working capital	ARS -5.3T
Working capital turnover	-22,214.72

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.03%
Dividend growth	30.81%
Dividend growth (10Y)	44.17%
Dividend growth (3Y)	93.54%
Dividend growth (5Y)	107.84%
Dividend growth years	4
Dividend payment date	2026-09-08
Dividend payment years	5
Dividend payout frequency	Semi-Annual
Dividend per share	ARS 1,040.86
Dividend yield	1.48%
Ex-dividend date	2026-08-07
Last dividend	ARS 358.06
Payout ratio	45.73%
Shareholder yield	1.51%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	ARS 68,065.17
1D price change	-2.4%
1M price change	4.19%
1M total return	4.19%
1W price change	5.56%
1W total return	5.56%
1Y price change	7.63%
1Y return CAGR	9.31%
1Y total return	9.3%
20-day SMA	ARS 66,522.50
200-day SMA	ARS 69,061.50
3M price change	4%
3M total return	4.65%
3Y price change	152.81%
3Y return CAGR	38.35%
3Y total return	164.86%
50-day SMA	ARS 65,909.50
50-day SMA vs 200-day SMA	50under200
52-week high	ARS 80,275.00
52-week high date	2026-07-03
52-week low	ARS 54,750.00
52-week low date	2025-10-27
5Y price change	1,020.64%
5Y return CAGR	64.07%
5Y total return	1,088.6%
6M price change	-0.92%
6M total return	-0.29%
All-time high	ARS 80,275.00
All-time high date	2026-07-03
All-time low	ARS 3,038.00
All-time low date	2020-09-04
Average true range (ATR)	ARS 1,476.20
Average volume	750.8
Change from 52-week high	-12.52%
Change from 52-week low	28.27%
Change from all-time high	-12.52%
Change from all-time low	2,211.55%
Change from open	-1.4%
Day's gap	-1.01%
Dollar volume	ARS 90.9M
High price	ARS 71,325.00
Low price	ARS 70,100.00
Monthly RSI	62.83
Open price	ARS 71,225.00
Position in 52-week range	10.2%
Previous close	ARS 71,950.00
Price vs 150-day SMA	3.17%
Price vs 20-day SMA	5.57%
Price vs 200-day SMA	1.68%
Price vs 50-day SMA	6.55%
Relative volume	1.72
RSI	61.64
Sharpe ratio	0.29
Sharpe ratio (3Y)	0.99
Sharpe ratio (5Y)	1.45
Sortino ratio	0.56
Sortino ratio (3Y)	1.68
Sortino ratio (5Y)	2.42
Volume	1.3K
Weekly RSI	54.85
YTD price change	-0.46%
YTD total return	1.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.5B
Shares change (QoQ)	-0.06%
Shares change (YoY)	-0.03%
Shares held by insiders	0.04%
Shares held by institutions	74.28%

Deeper analysis on BCBA/AZN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BCBA/AZN report

Is a complete BCBA/AZN research report available?

No complete published report is available for bcba/AZN (BCBA/AZN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BCBA/AZN (BCBA/AZN)

Price

Financial snapshot

Fair-value bridge

Latest news · BCBA/AZN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BCBA/AZN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BCBA/AZN

Frequently asked questions